Danish Registry Analysis Finds Consistent Safety After Switching to Infliximab Biosimilar GP1111

February 03, 2026

New Danish registry data confirm the safety of switching to infliximab biosimilars, showing low rates of serious adverse events in patients with inflammatory arthritis.

Q&A With Chelsee Jensen, PharmD: FDA Policy Shifts, Biosimilar Development Hurdles, and Market Access in 2026

February 02, 2026

Early Evidence Supports KM118 as a Biosimilar to Reference Pertuzumab

January 28, 2026

Milestone Approvals, Evolving PBM Models May Redefine the 2026 Biosimilar Landscape

January 27, 2026

FDA Draft Guidance on Biosimilars Is a Win for Patients; Now Congress Must Finish the Job

January 26, 2026

Vizient Report Emphasizes Biosimilar Successes, Impact of Inflation on Drug Spend

February 7th 2024

By Skylar Jeremias

Article

Vizient’s most recent Pharmacy Market Outlook report showcased the success of biosimilars while also emphasizing the impact of inflation on different drug classes, particularly in oncology and immunology.

Biosimilar Etanercept Similar to Enbrel in Persistence of Treatment, Cost Savings for Patients With RA

February 6th 2024

By Cameron Santoro

Article

Etanercept biosimilar SB4 is just as effective as the originator drug (Enbrel) in treating Australian patients with rheumatoid arthritis (RA), leading to significant cost savings.

BioRationality: Bringing the FDA and the USP Together to Revolutionize Biosimilars

February 5th 2024

By Sarfaraz K. Niazi, PhD

Article

In his latest column, Sarfaraz K. Niazi, PhD, highlights challenges in biosimilar development, emphasizing the crucial role of US Pharmacopeia (USP) and advocating for collaboration and standardized guidelines to expedite cost-effective development without compromising safety or efficacy.

Biosimilars Gastroenterology Roundup for January 2024—Podcast Edition

February 4th 2024

By Skylar Jeremias

Podcast

On this episode of Not So Different, we reminisce on all the major gastroenterology news from January, which brought several reports quantifying how the gastroenterology biosimilar market is progressing and marked the 1-year anniversary of adalimumab biosimilar competition in the US.

Patient-Reported Experiences on Adalimumab Biosimilar SB5 and Correlation With Treatment Persistence

February 3rd 2024

By Deana Ferreri, PhD

Article

The PERFUSE study in France on biosimilar adalimumab SB5 for inflammatory bowel disease reveals high satisfaction overall, but significant variations in training and survey response rates across sites suggest a potential lack of support during treatment switches.

The Top 5 Biosimilar Articles for the Week of January 29

February 2nd 2024

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of January 29, 2024.

Biosimilars Gastroenterology Roundup: January 2024

February 1st 2024

By Skylar Jeremias

Article

In addition to the several reports that have come out quantifying how the gastroenterology biosimilar market is progressing, January marks the 1-year anniversary of adalimumab biosimilar competition in the US.

SB15 Effective, Safe in Treating nAMD Before, After Switching

February 1st 2024

By Cameron Santoro

Article

A study found SB15, an aflibercept biosimilar, is just as effective as its reference drug Eylea, the current standard treatment for neovascular age-related macular degeneration (nAMD), a condition that causes vision loss.

Happy Birthday Adalimumab Biosimilars: Reflecting on the First Year of US Competition

January 31st 2024

By Skylar Jeremias

Article

The Center for Biosimilars® looks back at the first year of adalimumab biosimilars on the US market, including every product launch and approval as well as market trends and pricing strategies.

Eye on Pharma: Coherus Offloads Cimerli; Celltrion Files for CT-P47; Alvotech Shares Denosumab Results

January 30th 2024

By Skylar Jeremias

Article

Coherus Biosciences has sold its ranibizumab biosimilar (Cimerli) to Sandoz; Celltrion has completed its biologics license application filing for its tocilizumab biosimilar (CT-P47); Alvotech shares positive pharmacokinetic results for its denosumab biosimilar candidate.